Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Oct;138(4):648-50.
doi: 10.1016/j.ajo.2004.04.066.

Infliximab for chronic cystoid macular edema associated with uveitis

Nikos N Markomichelakis  1 , Panagiotis G Theodossiadis, Eygenia Pantelia, Semina Papaefthimiou, George P Theodossiadis, Petros P Sfikakis
Affiliations

Infliximab for chronic cystoid macular edema associated with uveitis

Nikos N Markomichelakis et al. Am J Ophthalmol. 2004 Oct.

Abstract

Purpose: To assess the efficacy of the anti-TNF monoclonal antibody infliximab in uveitis patients without clinically evident ocular inflammation and impaired visual acuity because of chronic cystoid macular edema (CME).

Design: Prospective, noncomparative, interventional case series.

Methods: Patients with refractory CME (14 eyes, mean duration of 14 months), associated with intermediate uveitis (n = 6), Adamantiades-Behcet disease (n = 2), adult-type vascular pseudotumor (n = 1), and HLAB27+-related uveitis (n = 1) received an intravenous infliximab infusion (5 mg/kg); five patients were retreated after 1 month.

Results: Macular thickness, measured by ocular coherence tomography, was reduced from 428 +/- 138 microm to 219 +/- 51 microm at 2 months postbaseline (P = .0001), while visual acuity increased from 0.41 +/- 0.18 to 0.83 +/- 0.17 (P < .00001). Anatomic and functional improvement was sustained at 6 months in all. No ocular or extra-ocular side effects were noted.

Conclusion: These promising results suggest that TNF may play an important pathogenetic role in chronic CME, thus, a controlled trial is warranted.

PubMed Disclaimer

LinkOut - more resources